OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

NeuroBo Pharmaceuticals (NASDAQ:NRBO – Get Free Report) is anticipated to announce its earnings results on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.89) per share ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

OPKO Health (OPK) and Entera Bio (ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a ...

The program combines OPKO's long-acting oxyntomodulin analog or OPK-88006 with Entera's proprietary N-Tab technology, and promising pharmacodynamic data has already been reported. The goal of the ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

The programme unites Opko's long-acting oxyntomodulin (OXM) analogue, OPK-88006 and Entera's N-Tab technology. Opko will hold 60% and Entera 40% ownership interests. The partnership will account ...

This new treatment combines OPKO's long-acting oxyntomodulin analog, OPK-88006, with Entera's N-Tab™ technology and shows promising data from preclinical studies. The companies plan to submit an ...

The treatment, which combines OPKO’s oxyntomodulin analog (OPK-88006) with Entera’s N-Tab™ technology, has shown favorable pharmacodynamic, pharmacokinetic, and bioavailability data from in ...